Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

Trial Profile

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Nonacog alfa (Primary) ; Rurioctocog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Therapeutic Use
  • Acronyms SPACE
  • Sponsors Baxalta; Baxter Healthcare Corporation
  • Most Recent Events

    • 13 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2015 Planned number of patients changed from 60 to 63 as per ClinicalTrials.gov record.
    • 17 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top